FDA
-
-
-
-
-
-
-
Omeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thromboti
-
-
-
-
-
-
-
Omeros Corporation to Announce Second Quarter Financial Results on Morning of August 9, 2023
-
-
-
-
-
-
-
Omeros (OMER) Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria
-
-
-
-
-
-
-
Omeros Corporation to Announce Fourth Quarter and Year End Financial Results on March 13, 2023
-
-
-
-
-
-
-
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
-
-
-
-
-
-
-
Omeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab
-
-
-
-
-
-
-
Omeros Corporation Reports First Quarter 2022 Financial Results
-
251,770 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All